Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction
Launched by ROHAN DHARMAKUMAR · Jun 7, 2024
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Index STEMI
- • Primary PCI
- • Able to complete Cardiac MR - STRAIN Protocol
- Exclusion Criteria:
- • Contraindication to CMR (Contrast Hypersensitivity, Metallic Implants, Abnormal Rhythms, breathing difficulties)
About Rohan Dharmakumar
Rohan Dharmakumar is a distinguished clinical trial sponsor dedicated to advancing medical research through innovative and rigorously designed studies. With a strong focus on cardiovascular health and metabolic diseases, Dharmakumar’s initiatives aim to bridge the gap between scientific discovery and clinical application. Leveraging a collaborative approach, the sponsor works closely with academic institutions, healthcare professionals, and regulatory bodies to ensure the integrity and efficacy of its trials. Committed to ethical standards and patient safety, Rohan Dharmakumar's efforts contribute significantly to the enhancement of therapeutic options and improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Indianapolis, Indiana, United States
Patients applied
Trial Officials
Rohan Dharmakumar, PhD
Study Director
Indiana University School of Medicine
Keyur P Vora, MD FACC
Principal Investigator
Indiana University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported